Is Ozempic safe if you have asthma or COPD?

Millions of people who take Ozempic also live with asthma or chronic obstructive pulmonary disease (COPD), because excess weight and airway disease often travel together. A fair question follows: does a drug that changes appetite and digestion do anything to your breathing?

The 2026 evidence gives an unusually clear two-part answer. GLP-1 drugs do not appear to harm the lungs, and in people who already have asthma or COPD they are linked to fewer serious flare-ups. This article walks through the safety data first, then the benefit signals, and it is careful throughout about what that evidence can and cannot prove.

Is Ozempic safe for the lungs?

The strongest evidence here is a safety study. A 2026 systematic review and meta-analysis in the Annals of the American Thoracic Society screened 9,086 records and pooled 123 studies of weight-loss drugs and their respiratory side effects.1

The review found that liraglutide, semaglutide and tirzepatide were not associated with more respiratory adverse events than placebo, and the randomized trials it drew on had a low risk of bias.1 That is the reassuring headline: across a large body of trials, these drugs did not appear to make breathing worse.

Respiratory infections still occur on the drugs. Nasopharyngitis, the medical name for the common cold, was frequent, ranging from about 4.1% to over 23.7% depending on the drug and how long people were followed.1 But the review found these infections were not clearly tied to the drug, the dose or the reason it was prescribed.1 In plain terms, colds happen on these drugs about as often as they happen anyway.

One honest limit sits inside the same review. Evidence focused specifically on people who already have asthma was sparse.1 So the reassurance is strongest for the general population's breathing, and thinner for asthma patients considered as a distinct group.

Can Ozempic help COPD?

Beyond safety, some 2026 data hint at benefit. A retrospective cohort study in QJM used the TriNetX global health network to compare adults aged 40 and older who had both COPD and type 2 diabetes and newly started a GLP-1 drug against similar patients who started other diabetes medicines.2

Over one year, GLP-1 users had a lower risk of acute respiratory failure than users of DPP-4 inhibitors (hazard ratio 0.77), sulfonylureas (0.80) and metformin (0.91).2 They also had lower rates of death, hospitalization, COPD flare-ups and pneumonia across all three comparisons.2

The pattern held across sex, age, flare-up history and inhaler regimen.2 But this is an observational study, so it can show that GLP-1 users did better, not that the drug caused it. People who are prescribed these drugs may differ in ways that also affect their lungs, which is a limit no matching can fully remove.

The three main 2026 sources behind this article. The safety review is a systematic review and meta-analysis; the COPD and asthma studies are retrospective cohorts that compared GLP-1 drugs with other diabetes medicines, so their findings are associations, not proof of cause and effect.123

The drugs do not appear to harm the lungs, and in people who already have asthma or COPD they are linked to fewer serious flare-ups. But linked is not the same as proven. The 2026 respiratory evidence, in one line

Can Ozempic help asthma?

The asthma picture is similar, and it comes with a useful caution built in. A multinational cohort study in Pharmacotherapy looked at 100,746 people who had both asthma and type 2 diabetes, comparing those who started a GLP-1 drug with those who started an SGLT-2 inhibitor, another common diabetes medicine.3

Over about 6 months, GLP-1 users had fewer asthma flare-ups (hazard ratio 0.88), fewer episodes of asthma symptoms (0.89) and less need for systemic steroids (0.79).3 On the surface, that is a clear win for the airways.

The caution is in the same paper. When the researchers extended follow-up to a full year, the flare-up benefit was no longer statistically significant (hazard ratio 0.95).3 A signal that shows up at 6 months but fades by 12 is a reason to be measured rather than triumphant, and the authors themselves call for randomized trials to test it properly.3

A much smaller study from Hong Kong pointed the same way, finding a significantly lower risk of hospital-treated asthma flare-ups on GLP-1 drugs, roughly half the risk seen with a comparison diabetes drug.4 But only 102 of its patients were taking a GLP-1 drug, so it supports the larger findings rather than standing on its own.4

Why might GLP-1 drugs help breathing?

Researchers offer two plausible reasons, and neither is settled. The first is weight loss. Excess weight worsens both asthma and COPD, and shedding weight is known to improve asthma control, so a drug that drives weight loss could help breathing indirectly.13

The second is inflammation. GLP-1 receptor agonists have anti-inflammatory effects, and asthma and COPD are both inflammatory diseases of the airways, so the drugs might act on the lungs more directly.2 The study authors raise this as a hypothesis, not an established mechanism.

Both ideas are reasonable, and both are still being tested. The cohort studies were not built to prove why the numbers moved, only to measure that they did, which is exactly why the results are described as associations.

What this means if you have asthma or COPD

The bottom line is reassuring but bounded. GLP-1 drugs do not appear to harm breathing, and if anything they are linked to fewer serious respiratory events in people who also have diabetes.123

What the evidence does not do is turn these drugs into asthma or COPD treatments. GLP-1 drugs are approved for type 2 diabetes, weight management and cardiovascular risk, and one drug is approved for sleep apnea, but none is approved to treat asthma or COPD.5 The benefit signals come entirely from retrospective studies in people with diabetes, where confounding is hard to rule out.

The practical rule is simple: keep taking your prescribed inhalers and controller medicines exactly as directed, and never start, stop or swap a respiratory medicine because of anything about a GLP-1 drug. If you have asthma or COPD and are considering or already taking Ozempic, tell the doctor who manages your breathing, so both conditions are handled together.

One scope note. This article is about asthma and COPD, the chronic diseases of the airways. That is a separate question from sleep apnea, where a different GLP-1 medicine already has its own approval and its own evidence, and it should not be lumped in with the airway findings here.

In one sentence: The 2026 evidence says GLP-1 drugs like Ozempic do not appear to harm breathing and are linked to fewer asthma and COPD flare-ups in people who also have diabetes, but those benefits are unproven associations, the drugs are not approved for either lung condition, and you should never change your inhaler on your own.